On May 29, 2026，the Center for Drug Evaluation of the National Medical Products Administration released the Technical Guidelines for Bioequivalence Studies of Iron Sucrose Injection (Draft for Public Comment)，for the first time explicitly encouraging the use of AI-driven real-world data simulation and automated BE analysis tools in the field of BE studies。This document indicates that China’s clinical evaluation system for generic drugs is accelerating its evolution toward intelligence and data-driven development，bringing substantial impact to segmented fields such as AI healthcare SaaS，clinical data governance，and cross-border compliance services。

Event Overview

On May 29, 2026，the official website of the Center for Drug Evaluation of the National Medical Products Administration publicly released the Technical Guidelines for Bioequivalence Studies of Iron Sucrose Injection (Draft for Public Comment)。The document clearly states that，under the premise of meeting scientific and regulatory requirements，applicants are encouraged to use AI-driven real-world data simulation methods to assist BE study design，and to adopt validated automated analysis tools to process pharmacokinetic parameters。The document is currently at the public consultation stage and has not yet been officially implemented。

Which Segmented Industries Will Be Affected

From an industry perspective，the directional statement in these guidelines is not a general technical advocacy，but focuses on a specific product (iron sucrose injection) and a specific technical pathway (AI+RWD+automated BE analysis)，with a clear industry-chain orientation in its impact：

• AI healthcare SaaS platform companies：As the guidelines include AI tools within the scope of BE study support for the first time，SaaS service providers with real-world data modeling capabilities，PK/PD automated analysis modules，and experience in adapting to NMPA submissions may see their technical solutions preferentially accepted by domestic applicants，thereby increasing overseas customers’ recognition of their compliance credibility。
• Clinical data governance service providers targeting emerging markets：The document emphasizes “traceable data quality and verifiable algorithm logic”，compelling companies that provide integrated localized website development + data governance services for customers in Southeast Asia，the Middle East，Latin America，and other regions to strengthen the engineering implementation capabilities of their platforms in modules such as GCP compatibility，multi-source heterogeneous data cleaning，and audit trail。
• Generic drug R&D CRO and CDMO companies：Iron sucrose injection is a complex injectable product，with BE studies that are difficult and time-consuming。If AI simulation tools can shorten the pre-experiment cycle or reduce failure rates，they will directly affect project pricing strategies，resource scheduling logic，and the depth of technical collaboration with applicants。

What Key Points Relevant Companies or Practitioners Should Focus On and How They Should Respond at Present

Monitor Subsequent Official Statements or Policy Changes

The current document is only a draft for public comment。Whether the final version will retain the expression “AI-driven”，whether it will be expanded to other categories of complex injectables，and whether supporting tool validation guidelines will be issued all require continuous tracking of updates on the CDE official website and subsequent training arrangements。

Pay Attention to Differences in Key Markets’ Acceptance of AI Tools

Drug regulatory authorities in some Southeast Asian countries have not yet established precedents for reviewing AI clinical tools；the Middle East places greater emphasis on localized deployment and data sovereignty。Companies should not directly extrapolate domestic policy signals as a passport for overseas market access，but should assess regulatory maturity and the pace of technology adoption by market。

Distinguish Policy Signals from Actual Business Implementation

The guidelines are technical recommendations rather than mandatory requirements，and traditional BE studies remain the mainstream pathway at this stage。Companies should avoid prematurely positioning AI tools as a core selling point for large-scale marketing investment。It is more appropriate to first complete end-to-end process testing for at least 1–2 iron sucrose-type projects in internal validation scenarios。

Organize Verifiability Evidence for the Existing Toolchain in Advance

If AI-assisted BE analysis services are already being provided，it is necessary to systematically organize documentation on algorithm principles，explanations of input-output mapping relationships，historical validation cases (including deviation analysis)，and comparison results with gold-standard tools such as Phoenix WinNonlin，so as to reserve a response foundation for future customer due diligence or regulatory inquiries。

Editor’s Viewpoint / Industry Observation

Observably, this guidance is less a regulatory mandate and more a strategic signal — one that acknowledges the growing maturity of AI tools in specific, well-defined clinical pharmacology contexts. It does not represent immediate market authorization for AI-based BE conclusions, nor does it lower scientific or evidentiary thresholds. Rather, it opens a formal channel for dialogue between developers and regulators on how such tools can be responsibly integrated into existing frameworks. The real test will be whether subsequent draft guidelines extend this language beyond sucrose iron — and whether regional regulators outside China begin referencing similar principles in their own consultations.

Conclusion：
The core significance of this draft for public comment lies in the fact that，for the first time in a national-level technical guidance document，it provides a clear policy interface for AI tools to participate in BE studies。However，this interface is currently limited to the level of “encouraged use” and does not yet constitute a mandatory pathway or an approval shortcut。For the industry，it is more appropriate to understand it as a starting signal for technical compliance capability building，rather than an immediate trigger for commercial implementation。Companies should advance tool validation and scenario adaptation with a prudent and pragmatic attitude，avoiding resource misallocation caused by policy misinterpretation。

Information Source Statement：
Primary source：Official website of the Center for Drug Evaluation of the National Medical Products Administration (Technical Guidelines for Bioequivalence Studies of Iron Sucrose Injection (Draft for Public Comment) released on May 29, 2026)。
Items requiring continuous observation：the release date of the final version of these guidelines，detailed supporting validation requirements，and whether they will be expanded to other complex injectable products。